Moreover, other studies compared BMD loss reduction derived from the inhibition of T cell co-stimulation, in comparison with conventional synthetic DMARDs and TNFα-inhibitors, and observed a bone-sparing effect of abatacept in RA patients; none of the patients in the cohorts were treated with rituximab [70,71]. The gene discussed is TNF; the disease is rheumatoid arthritis.